MCL-1 is a well characterized inhibitor of cell death that has also been shown to be a 40 regulator of mitochondrial dynamics in human pluripotent stem cells (hPSCs). We used 41 cardiomyocytes derived from hPSCs (hPSC-CMs) to uncover whether MCL-1 is crucial for cardiac 42 function and survival. Inhibition of MCL-1 by BH3 mimetics, resulted in the disruption of 43 mitochondrial morphology and dynamics as well as disorganization of the actin cytoskeleton. 44 Interfering with MCL-1 function affects the homeostatic proximity of DRP-1 and MCL-1 at the outer 45 mitochondrial membrane, resulting in decreased functionality of hPSC-CMs. BH3 mimetics 46 targeting MCL-1 are promising anti-tumor therapeutics. Cardiomyocytes display abnormal 47 functional cardiac performance even after caspase inhibition, supporting a non-apoptotic activity 48 of MCL-1 in hPSC-CMs. Progression towards using BCL-2 family inhibitors, especially targeting 49 MCL-1, depends on understanding not only its canonical function in preventing apoptosis, but 50 also in the maintenance of mitochondrial dynamics and function. 51 52 53 54 55 56 57 58 59 60 61
Introduction
been implicated as a mechanism for the onset of dilated cardiomyopathy (Dorn, 2013) . 91
Mitochondria also regulate cardiomyocyte differentiation and embryonic cardiac development 92 (Kasahara et al., 2013; Kasahara and Scorrano, 2014; Cho et al., 2014) . However, there is limited 93 information about the mechanisms used by cardiomyocytes to minimize the risks for apoptosis, 94 especially in cells derived from highly sensitive stem cells (Imahashi et al., 2004; Murriel et al., 95 2004; Gama and Deshmukh, 2012; Dumitru et al., 2012; Walensky, 2012) . 96
Ultrastructural changes have long been observed in response to alterations in oxidative 97 metabolism (Hackenbrock, 1966; Khacho et al., 2016) . It has become increasingly clear that 98 individual mitochondrial shape changes can also have dramatic effects on cellular metabolism. 99
Mitochondrial morphology and cristae structure are influenced by fission and fusion events; 100 subsequently, ETC complexes that reside on the inner mitochondrial membrane are disrupted 101 upon aberrant fission (Chan, 2007) . Several human diseases, such as MELAS (Muscle atrophy, 102
Encephalopathy, Lactic Acidosis, Stroke-like episodes) and Dominant Optic Atrophy (DOA), are 103 associated with mutations in the mitochondrial dynamics and mitochondrial metabolism 104 machineries (Chan, 2007; Hsu et al., 2016) . Likewise, many neurological conditions, including 105
Parkinson's disease, Huntington's disease, and Charcot-Marie Tooth Type 2 syndrome, can 106 originate from alterations in mitochondrial dynamics and metabolic regulation (Itoh et al., 2013; 107 Burté et al., 2015) . Besides neurological conditions, several studies in the heart suggest that 108 alterations in mitochondrial dynamics causes abnormal mitochondrial quality control, resulting in 109 the buildup of defective mitochondria and reactive oxygen species (ROS) (Galloway and Yoon, 110 2015; Song et al., 2017) . Interestingly, it has been shown that modulating the production of ROS 111 can favor or prevent differentiation into cardiomyocytes (Buggisch et al., 2007; Murray et al., 112 2014) . Thus, specific metabolic profiles controlled by mitochondrial dynamics are likely critical for 113 hiPSC-CMs, since they can influence cell cycle, biomass, metabolite levels, and redox state 114 (Zhang et al., 2012) . 115
It is not completely understood how dynamic changes in metabolism affect cardiomyocyte 116 function. Deletion of MCL-1 in murine heart muscle resulted in lethal cardiomyopathy, reduction 117 of mitochondrial DNA (mtDNA), and mitochondrial dysfunction (Wang et al., 2013) . Inhibiting 118 apoptosis via concurrent BAK/BAX knockout allowed for the survival of the mice; conversely, the 119 mitochondrial ultrastructure abnormalities and respiratory deficiencies were not rescued. These 120 results indicate that MCL-1 also has a crucial function in maintaining cell viability and metabolic 121 profile in cardiomyocytes. Despite these efforts, the non-apoptotic mechanism by which MCL-1 122 specifically functions in cardiomyocytes is still unknown. Furthermore, a role for MCL-1 in the 123 regulation of mitochondrial dynamics in cardiac cells has not yet been defined. Here we describe 124 findings that MCL-1 is essential for the survival of hiPSC-CMs by maintaining mitochondrial 125 morphology and function. 
MCL-1 inhibition causes severe defects in hiPSC-CM mitochondrial network. 130
In a previous report, MCL-1 inhibition using RNAi also resulted in mitochondria morphology 142 defects including severe cristae disruption and remarkable vacuolation in the mitochondrial matrix 143 (Guo et al., 2018) . Recent reports have determined that MCL-1 functions not only as an apoptosis 144 regulator but also as a modulator of mitochondrial morphology and dynamics (Perciavalle et al., 145 2012; Morciano et al., 2016; Rasmussen et al., 2018) . Thus, we hypothesized that inhibiting MCL-146 1 with BH3 mimetics would affect the functionality of human cardiomyocytes, due to the disruption 147 of crucial MCL-1 interactions with the mitochondrial dynamics machinery, which ultimately will 148 lead to cell death. 149
150

MCL-1 inhibition affects contractility of iPSC-CMs and myofibril assembly in a caspase-151 independent manner. 152
MCL-1 inhibition by S63845 was shown to have minimal effects on murine ejection fraction 153 (Kotschy et al., 2016 ) and on overall cardiac function in human cardiomyocytes (Guo et al., 2018) . 154
These results are intriguing considering previous studies reporting that MCL-1 deletion from 155 murine cardiomyocytes has severe effects on mitochondrial morphology and cardiac function, 156 which were not rescued by co-deletion of BAK and BAX (Wang et al., 2013) . We treated human 157 iPSC-CMs with S63845, while inhibiting caspase activity, and measured spontaneous beating 158 using phase-contrast live-cell imaging. We observed lower numbers of beating cells when treated 159 with 1-2 μM MCL-1i (S63845), and the cells that were beating appeared to beat more slowly 160 (Figure S1A-C). To assess these defects more rigorously, we plated cells on a multi-electrode 161 array (MEA) plate and examined cardiac function using the Axion Biosystems analyzer (Clements 162 and Thomas, 2014) ( Figure 2A ). We observed that MCL-1 inhibition caused severe defects in 163 cardiomyocyte functionality after just 18 hours of the first treatment ( Figure 2B -D). In particular, 164 beat period irregularity was significantly increased ( Figure 2B ), while spike amplitude and spike 165 slope means were decreased ( Figure 2C -D). The differences between beat period mean and 166 conduction velocity mean at this time point were not significant (Figure S1D-E); however, at just two days of treatment with MCL-1 inhibitor, cardiomyocytes became quiescent and stopped 168 beating altogether (Figure S1F-J). These results implicate tachycardia and arrhythmia 169 phenotypes in cardiomyocytes exposed to S63845. To probe whether these cells are also 170 sensitive to BCL-2 inhibition, we also treated hiPSC-CMs with the BCL-2 inhibitor Venetoclax 171 (ABT-199) (Souers et al., 2013) . In the same treatment paradigm, ABT-199 had no effect on 172 hiPSC-CM functionality compared to control cells (Figure S1C-G). These results suggest that 173 hiPSC-CMs are highly dependent on MCL-1, but not BCL-2, for function and survival. Intriguingly, 174
we also observed significant changes in the structure and integrity of the actin network and 175 subsequent myofibril organization in cells treated with MCL-1 inhibitor ( Figure 2E ). hiPSC-CMs 176 displayed poor Z-line organization, lower density of F-actin, and increased presence of stress 177 fibers ( Figure 2E ). Blinded quantification of F-actin organization revealed that MCL-1 inhibitor-178 treated cells had significantly less organized myofibril structure ( Figure 2F ). 179 180
MCL-1 co-localizes with mitochondrial dynamics proteins in hiPSC-CMs, and S63845 181 disrupts MCL-1:DRP-1 co-localization. 182
Since MCL-1 inhibition disrupted mitochondrial network integrity in hiPSC-CMs and MCL-1 183 depletion affects mitochondrial dynamics proteins (Rasmussen et al., 2018) , we next examined 184 the effects of MCL-1 inhibition on the expression levels of key mitochondrial proteins. MCL-1 185 inhibitor-treated cells had a significant increase in the expression levels of DRP-1 ( Figure 3A Figure S3A ). We then 189 assessed whether MCL-1 interacts with these GTPases responsible for maintaining mitochondrial 190 morphology and dynamics using in situ proximity ligation assay (PLA). Our data shows that MCL-191 1 is in close proximity to both DRP-1 and OPA1 ( Figure 3E -H). PLA puncta were quantified and 192 normalized to the number of puncta in the control sample ( Figure S2B ). The co-localization of MCL-1 with DRP-1, but not OPA1, was disrupted upon inhibition of MCL-1 with S63845 ( Figure  194 3E-F), suggesting that MCL-1 interacts with DRP-1 through its BH3 binding groove. Since the 195 interaction with OPA1 was not disturbed ( Figure 3G -H), it is possible that MCL-1 interacts with 196 OPA1 either through a different domain, or with a different isoform of OPA1 in hiPSC-CMs than 197 in hPSCs (Rasmussen et al., 2018) . Another possibility is that, upon differentiation, the small 198 molecule can no longer penetrate the inner mitochondrial membrane. 199 DRP-1 is shuttled to the outer mitochondrial membrane upon activation. In our previous 200 study, we showed that MCL-1 depletion decreases the activity of DRP-1 and promotes 201 mitochondrial elongation (Rasmussen et al., 2018) . Since MCL-1 inhibition with S63845 appeared 202 to cause mitochondrial fragmentation in cardiomyocytes, we hypothesized that more DRP-1 203 would be activated and brought to the mitochondria to initiate fission. However, levels of active 204 DRP-1 (pDRP-1 S616) that co-localized with mitochondria decreased in S63845-treated hiPSC-205
CMs ( Figure S3A 
MCL-1 inhibition results in iPSC-CM death 217
To examine whether iPSC-CMs treated with MCL-1 inhibitor were still sensitive to caspase-218 mediated cell death, we treated the cells with increasing doses of S63845 and examined the activation of caspase-3 and caspase-7 in the absence of QVD. Cells responded to S63845 in a 220 dose-dependent manner after 48 hours, with 1-2 μM MCL-1i inducing the most caspase activity 221 ( Figure 5A ). To examine the possibility that cardiomyocytes were dying independently of caspase-222 3 activation, we used the Incucyte live cell imaging system and indeed found similar levels of cell 223 death with and without caspase inhibition ( Figure S4A-B) . These results indicate that iPSC-CMs 224 are committing to a caspase-independent cell death in response to MCL-1 inhibition. Previous 225 reports have established that iPSC-derived cardiomyocytes are more similar to immature 226 progenitor cells. To test the possibility that the effects were caused by this immature state, we 227 used a previously published hormone-based method for cardiomyocyte maturation ( Figure 5B cardiac functionality at lower doses, we treated hiPSC-CMs for two weeks (with treatments every 240 two days) with 100 nM S63845. We also treated the cells with the BCL-2 inhibitor ABT-199 (100 241 nM) and a combination of S63845 + ABT-199 (100 nM each). While there were no significant 242 differences between treatments in the spike slope mean ( Figure 6B BCL-2 inhibition had little effect on mitochondrial network organization and virtually no effect on 251 myofibril organization ( Figure 6H and Figure S5E ). These results further support the idea that with changes in metabolism to support cell-type specific processes (Folmes et al., 2016) . Since 262 mitochondrial morphology is tightly coupled to cellular respiration via integrity of the ETC, future 263 studies will aim to investigate the metabolic changes that occur when MCL-1 is deleted in iPSC-264
CMs. Cardiac contractions depend on energy from these metabolic pathways, and thus cardiac 265 mitochondria are forced to work constantly and likely require strict quality control mechanisms to 266 maintain a functioning state (Dorn et al., 2015) . This quality control process could depend in part 267 on MCL-1. In support of this idea, our studies indicate that MCL-1 activity is essential for iPSC-268 CM viability and maturation, which could be linked to MCL-1's non-apoptotic function at the 269 mitochondrial matrix. Our results emphasize the need for a more complete molecular 270 understanding of MCL-1's mechanism of action in human cardiomyocytes as it may reveal new approaches to prevent potential cardiac toxicities associated with chemotherapeutic inhibition of 272 MCL-1. Plasmid encoding mito-tdEos (Addgene #57644) was transfected using ViaFect (Promega 308 #E4981) as described in the manufacturer protocol. Cells were maintained until optimal 309 transfection efficiency was reached before cells were imaged. 310
311
Immunofluorescence 312
For immunofluorescence, cells were fixed with 4% paraformaldehyde for 20 min and 313 permeabilized in 1% Triton-X-100 for 10 min at room temperature. After blocking in 10% BSA, 314 cells were treated with primary and secondary antibodies using standard methods. Cells were 315 
Impedance assays 334
The Axion Biosystems analyzer was used to measure contractility and impedance in iPSC-CMs. 335
Cells were plated on 48-well CytoView MEA plates and maintained for 10 days before treatment 336 and recordings. Recordings were taken for 5 minutes approximately two hours after media 337 change.Cells were assayed using the standard cardiac analog mode setting with 12.5 kHz 338 sampling frequency to measure spontaneous cardiac beating. The Axion instrument was 339 controlled using Maestro Pro firmware version 1. 
Proximity Ligation Assay (PLA) 343
Cells were seeded onto fibronectin-coated 8-chamber MatTek glass slides (#CCS-8) at 10,000 344 cells/chamber. After treatments, cells were fixed in 4% PFA for 20 min and permeabilized in 1% 345
Triton-100-X for 10 min at room temperature. Following fixation, the DuoLink proximity ligation For MEA experiments, means from triplicate biological replicates (each with three technical 385 replicate wells) for each measurement were plotted and significance was determined by two-way 386
ANOVA. 387
For PLA experiments, images were quantified using Fiji. Briefly, background noise levels were 388 subtracted, and number of puncta per ROI was normalized to mitochondrial area. ROIs in at least 389 5 cells per condition were quantified in three independent experiments. 390
Quantification of actin organization was performed in a blinded fashion and percentages of each 391 category are displayed. Cell viability measured using the Incucyte live cell imaging system was 392 performed by automatic segmentation of nuclei in Fiji, followed by subtraction of dead cells as 393 indicated by fragmented nuclei and rounded phenotype.
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